Unicycive Therapeutics (UNCY) Interest & Investment Income (2023 - 2026)
Unicycive Therapeutics posted quarterly Interest & Investment Income of $394000.0 for Q1 2026, up 74.34% year-on-year from $226000.0 in Q1 2025, and up 12.25% on a QoQ basis from $351000.0 in Q4 2025.
Unicycive Therapeutics (UNCY) has 4 years of Interest & Investment Income data on file, last reported at $394000.0 in Q1 2026.
- For the quarter ending Q1 2026, Interest & Investment Income rose 74.34% year-over-year to $394000.0; the trailing twelve-month figure through Mar 2026 stood at $1.2 million (down 16.85% YoY), and the FY2025 full-year result was $1.0 million, down 19.75% from the prior year.
- Interest & Investment Income for Q1 2026 stood at $394000.0, up from $351000.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $462000.0 in Q2 2024 and bottomed at $14000.0 in Q1 2023.
- The 4-year median for Interest & Investment Income is $234000.0 (2023), against an average of $252384.6.
- The widest annual swing landed in 2024, when Interest & Investment Income surged 392.86%; it then tumbled 66.45% in 2025.
- A 4-year view of Interest & Investment Income shows it stood at $140000.0 in 2023, then jumped by 124.29% to $314000.0 in 2024, then increased by 11.78% to $351000.0 in 2025, then gained by 12.25% to $394000.0 in 2026.
- The last three Interest & Investment Income figures came in at $394000.0 (Q1 2026), $351000.0 (Q4 2025), and $279000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 7.90 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 114.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 305,000.00 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 26.60 Mn |
| 10 | Unicycive Therapeutics | 181.94 Mn | 127.36 Mn | - | 394,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 394,000.00 |
| Dec 31, 2025 | 351,000.00 |
| Sep 30, 2025 | 279,000.00 |
| Jun 30, 2025 | 155,000.00 |
| Mar 31, 2025 | 226,000.00 |
| Dec 31, 2024 | 314,000.00 |
| Sep 30, 2024 | 416,000.00 |
| Jun 30, 2024 | 462,000.00 |
| Mar 31, 2024 | 69,000.00 |
| Dec 31, 2023 | 140,000.00 |
| Sep 30, 2023 | 227,000.00 |
| Jun 30, 2023 | 234,000.00 |
| Mar 31, 2023 | 14,000.00 |